Trials of Roche's Perjeta show it could help extend the lives of women with advanced breast cancer by over a year compared to existing treatments. The results from the CLEOPATRA study are a ...
Roche's Perjeta has been launched today in the UK for use in women with HER2-positive breast cancer before surgery – but, as with many new cancer drugs, access to treatment is uncertain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback